Andrew John Matthew Clark
Chairman at vasopharm GmbH
Net worth: 226 829 $ as of 2024-04-29
Profile
Andrew John Matthew Clark was the founder of Reabourne Ltd., which was founded in 1995 where he held the title of Portfolio Manager from 1995 to 2003.
He is currently the Chairman-Supervisory Board at vasopharm GmbH.
Dr. Clark's former positions include Director at Liminal BioSciences, Inc., Senior Independent Non-Executive Director at Lifeline Scientific, Inc., and Director at Hologic Ltd.
Dr. Clark received a doctorate degree from the University of St. Andrews.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-04-30 | 3,066,502 ( 1.08% ) | 226 829 $ | 2024-04-29 |
Andrew John Matthew Clark active positions
| Companies | Position | Start |
|---|---|---|
vasopharm GmbH
 vasopharm GmbH Pharmaceuticals: MajorHealth Technology vasopharm GmbH operates as a pharmaceutical company. It discovers and develops novel therapeutics for the treatment of cerebro and cardiovascular diseases and their consequences. The firm focuses on therapeutics influencing the bioavailability of nitric oxide. The company was founded by Harald Schmidt and Ulrich Walter in July 1998 and is headquartered in Wuerzburg, Germany. | Chairman | - |
Former positions of Andrew John Matthew Clark
| Companies | Position | End |
|---|---|---|
| Reabourne Ltd. | Founder | 2002-12-31 |
| LIMINAL BIOSCIENCES INC. | Director/Board Member | - |
| LIFELINE SCIENTIFIC, INC | Director/Board Member | - |
Hologic Ltd.
 Hologic Ltd. Medical SpecialtiesHealth Technology Hologic Ltd. manufactures life sciences products and services with two divisions, Molecular Diagnostics and Research Products & Services. The firm has laboratories, manufacturing and operations in the USA, UK and France. It provides test kits, reagents and services to two synergistic markets. It focuses on these niche opportunities with products, patents, expertise and acquisitions. The company was founded in 1992 and is headquartered in Wythenshawe, the United Kingdom. | Director/Board Member | - |
Training of Andrew John Matthew Clark
| University of St. Andrews | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| LIMINAL BIOSCIENCES INC. | Health Technology |
| Private companies | 4 |
|---|---|
Lifeline Scientific, Inc.
 Lifeline Scientific, Inc. Medical SpecialtiesHealth Technology Lifeline Scientific, Inc. engages in the development and marketing of advanced medical products and services. It focuses on tissue testing technologies. It also intends to provide more and better quality organs, tissues and cells, in support of transplant professionals worldwide, and the life-saving services. The company was founded by David Kravitz on October 1, 1998 and is headquartered in Itasca, IL. | Health Technology |
Hologic Ltd.
Hologic Ltd. Medical SpecialtiesHealth Technology Hologic Ltd. manufactures life sciences products and services with two divisions, Molecular Diagnostics and Research Products & Services. The firm has laboratories, manufacturing and operations in the USA, UK and France. It provides test kits, reagents and services to two synergistic markets. It focuses on these niche opportunities with products, patents, expertise and acquisitions. The company was founded in 1992 and is headquartered in Wythenshawe, the United Kingdom. | Health Technology |
vasopharm GmbH
vasopharm GmbH Pharmaceuticals: MajorHealth Technology vasopharm GmbH operates as a pharmaceutical company. It discovers and develops novel therapeutics for the treatment of cerebro and cardiovascular diseases and their consequences. The firm focuses on therapeutics influencing the bioavailability of nitric oxide. The company was founded by Harald Schmidt and Ulrich Walter in July 1998 and is headquartered in Wuerzburg, Germany. | Health Technology |
| Reabourne Ltd. |
- Stock Market
- Insiders
- Andrew John Matthew Clark
